Biomarin Pharmaceutical (BMRN) Goodwill & Intangibles (2009 - 2026)

Biomarin Pharmaceutical has disclosed Goodwill & Intangibles across 18 years of filings, most recently posting $400.9 million for Q1 2026.

• Quarterly Goodwill & Intangibles fell 9.62% year-over-year to $400.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $400.9 million (down 9.62% YoY) and the FY2025 annual result came in at $410.0 million, down 9.18% from the prior year.
• Goodwill & Intangibles declined to $400.9 million in Q1 2026, from $410.0 million in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $570.4 million in Q1 2022 and troughed at $400.9 million in Q1 2026.
• A 5-year average of $482.7 million and a median of $475.9 million in 2024 frame the typical range for Goodwill & Intangibles.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles fell 4.22% — and 2023, when it fell 10.44%.
• Tracing BMRN's Goodwill & Intangibles over 5 years: stood at $534.8 million in 2022, then declined by 8.2% to $490.9 million in 2023, then decreased by 8.03% to $451.5 million in 2024, then declined by 9.18% to $410.0 million in 2025, then declined by 2.24% to $400.9 million in 2026.
• Business Quant data shows BMRN's Goodwill & Intangibles at $400.9 million in Q1 2026, $410.0 million in Q4 2025, and $429.3 million in Q3 2025.